Avenue Therapeutics (ATXI) Competitors $0.24 +0.01 (+4.65%) As of 04/30/2025 01:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATXI vs. PALI, KZIA, ONVO, HEPA, SPRC, VRAX, ARAV, ENVB, RDHL, and SNPXShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include Palisade Bio (PALI), Kazia Therapeutics (KZIA), Organovo (ONVO), Hepion Pharmaceuticals (HEPA), SciSparc (SPRC), Virax Biolabs Group (VRAX), Aravive (ARAV), Enveric Biosciences (ENVB), RedHill Biopharma (RDHL), and Synaptogenix (SNPX). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Palisade Bio Kazia Therapeutics Organovo Hepion Pharmaceuticals SciSparc Virax Biolabs Group Aravive Enveric Biosciences RedHill Biopharma Synaptogenix Avenue Therapeutics (NASDAQ:ATXI) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership. Do insiders and institutionals hold more shares of ATXI or PALI? 17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 1.8% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ATXI or PALI more profitable? Palisade Bio's return on equity of -148.51% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avenue TherapeuticsN/A -471.57% -296.50% Palisade Bio N/A -148.51%-115.16% Which has stronger valuation & earnings, ATXI or PALI? Avenue Therapeutics has higher earnings, but lower revenue than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvenue TherapeuticsN/AN/A-$10.38M$18.350.01Palisade Bio$250K13.65-$12.30M-$10.92-0.07 Which has more volatility and risk, ATXI or PALI? Avenue Therapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Do analysts rate ATXI or PALI? Palisade Bio has a consensus target price of $23.00, suggesting a potential upside of 2,863.54%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts plainly believe Palisade Bio is more favorable than Avenue Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Palisade Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ATXI or PALI? In the previous week, Palisade Bio had 2 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for Palisade Bio and 0 mentions for Avenue Therapeutics. Palisade Bio's average media sentiment score of 1.43 beat Avenue Therapeutics' score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media. Company Overall Sentiment Avenue Therapeutics Neutral Palisade Bio Positive Does the MarketBeat Community prefer ATXI or PALI? Avenue Therapeutics received 137 more outperform votes than Palisade Bio when rated by MarketBeat users. Likewise, 60.25% of users gave Avenue Therapeutics an outperform vote while only 50.00% of users gave Palisade Bio an outperform vote. CompanyUnderperformOutperformAvenue TherapeuticsOutperform Votes14760.25% Underperform Votes9739.75% Palisade BioOutperform Votes1050.00% Underperform Votes1050.00% SummaryPalisade Bio beats Avenue Therapeutics on 10 of the 16 factors compared between the two stocks. Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$759,000.00$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio0.017.4422.4818.48Price / SalesN/A242.70395.10103.59Price / CashN/A65.8538.1834.62Price / Book0.136.516.774.25Net Income-$10.38M$143.21M$3.22B$248.23M7 Day Performance-3.72%1.98%1.50%0.89%1 Month Performance-16.97%6.89%4.01%3.53%1 Year Performance-94.94%-2.52%16.16%5.08% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics1.2153 of 5 stars$0.24+4.7%N/A-95.2%$759,000.00N/A0.014PALIPalisade Bio3.2421 of 5 stars$0.71-1.6%$23.00+3,147.7%-87.1%$3.11M$250,000.00-0.0510Gap DownKZIAKazia Therapeutics3.7785 of 5 stars$3.09-6.4%$11.50+272.2%-78.6%$3.11M$2.31M0.0012ONVOOrganovo0.569 of 5 stars$1.75+1.7%N/AN/A$2.98M$122,000.00-2.0620Gap UpHEPAHepion Pharmaceuticals0.2703 of 5 stars$0.27-16.2%N/A-99.6%$2.96MN/A-0.0620News CoverageGap DownSPRCSciSparc0.9581 of 5 stars$0.27-3.4%N/A-80.5%$2.96M$1.75M0.004Short Interest ↓Positive NewsVRAXVirax Biolabs Group2.3804 of 5 stars$0.91-8.1%$3.00+228.6%+55.6%$2.95M$84,872.000.005Short Interest ↑ARAVAraviveN/A$0.04flatN/AN/A$2.95M$6.99M0.0020High Trading VolumeENVBEnveric Biosciences2.6458 of 5 stars$1.19+1.7%$10.00+740.3%-90.6%$2.94MN/A-0.0320Positive NewsRDHLRedHill Biopharma0.8864 of 5 stars$2.17-4.0%N/A-99.2%$2.89M$8.04M0.00210Analyst ForecastGap DownSNPXSynaptogenix2.7766 of 5 stars$2.05-3.3%$14.00+582.9%-48.7%$2.85MN/A-0.194Positive NewsGap Down Related Companies and Tools Related Companies Palisade Bio Alternatives Kazia Therapeutics Alternatives Organovo Alternatives Hepion Pharmaceuticals Alternatives SciSparc Alternatives Virax Biolabs Group Alternatives Aravive Alternatives Enveric Biosciences Alternatives RedHill Biopharma Alternatives Synaptogenix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXI) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATXI Stock Free ATXI Stock Alerts